A new report shows that most US-based health plans now cover at least 1 of the 2 FDA-approved biosimilars currently available in the marketplace.
A new report produced by Avalere shows that most US-based health plans cover at least 1 of the 2 FDA-approved biosimilars currently available in the marketplace.
From April 11 to May 1 of 2017, Avalere researchers conducted an online survey of US-based health insurers. Drawing from a panel of health plan personnel, including medical directors, pharmacy directors, and other decision-makers, the researchers arrived at a pool of 50 qualified representatives who spoke on behalf of 45 health plans that cover 183 million individuals in the United States.
The responses collected by the researchers showed that 81% of plans cover at least 1 biosimilar product. When asked to specify the reasons that they have elected to cover biosimilar treatments, the health plan representatives gave the following as key factors in their decision-making:
About 1% of participants did not specify any factors that had been key to their decisions.
The researchers also examined ways in which health plans cover biosimilar filgrastim (Zarzio) and infliximab (Inflectra). In the 2 years since the launch of biosimilar filgrastim, approximately 94% of employer-sponsored insurance plans have opted to cover the biosimilar product, and 42% have placed it in their preferred-brand tiers, which reduces patients' out-of-pocket costs for filgrastim treatment. This preferred-brand tier placement for the biosimilar is in line with that of its competitors, including Granix, Neulasta, and Neupogen, which have achieved preferred-brand tier placement averaging 45%. Only 6% of plans did not cover biosimilar filgrastim, while 11% of plans, on average, did not cover the competitor products.
The report’s authors suggest that these results demonstrate a growing familiarity with biosimilar products, and that payers may not be waiting for the FDA to give biosimilar products interchangeable status before adopting the products for use.
While the uptake of biosimilar filgrastim by payers may be impressive, an analysis of plans covering infliximab does not demonstrate such strong results; only 7% of plans have placed the product in their preferred-brand tiers, while competitive products including Humira, Orencia, Remicade, and others, have achieved an average of 35% preferred-brand tier placement. Competitor products were, on average, denied coverage by 14% of health plans, 58% of plans did not cover the biosimilar infliximab.
According to the report’s authors, the case of biosimilar infliximab highlights the slow uptake of cost-saving biosimilar products in the US market. The authors state that policy considerations, market factors, and intellectual property-related challenges all currently play a role in curbing the uptake of these products, but point to the recent Supreme Court ruling in the case of Sandoz vs Amgen (which effectively eliminated a 180-day waiting period after FDA approval before a developer could launch a biosimilar product) as a step in the direction of swifter biosimilar uptake.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
BioRationality: Commemorating the 15th Anniversary of the BPCIA
April 8th 2025Affirming that analytical characterization is often sufficient for biosimilar approval, minimizing unnecessary clinical testing, and enhancing FDA-led education to counter stakeholder misconceptions are key recommendations put forth in this opinion piece by Sarfaraz K. Niazi, PhD.